Chronic hepatitis B is the leading cause of hepatocellular carcinoma (HCC). Oncolytic virotherapy (OV) is an emerging tool to treat cancer. However, one challenge of OV is that our immune system may produce neutralizing antibodies, which impaired its efficacy.

While on the other hand, antibody production against surface glycoprotein of HBV is inhibited in chronic hepatitis B. So can we use the HBV glycoprotein to pseudotype OV (e.g. VSV, measles, MLV), thereby circumvent the host humoral immunity? Can such viruses be used to treat HCC caused by chronic hepatitis B?


protected by Community Mar 21 '17 at 11:58

Thank you for your interest in this question. Because it has attracted low-quality or spam answers that had to be removed, posting an answer now requires 10 reputation on this site (the association bonus does not count).

Would you like to answer one of these unanswered questions instead?

Browse other questions tagged or ask your own question.